In the Spotlight...
Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression
Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis
Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib
Humoral determinants of checkpoint immunotherapy
Previous Digests
Novel binder designs mimic TCR specificity for pMCH-I
August 6, 2025
T cell receptors (TCRs) are highly specific for peptide–MHC (pMHC) complexes, allowing for recognition of specific intracellular antigens, and making them extremely useful in targeting specific target cells. However, TCRs that target specific pMHCs are often difficult to identify...
New nanobody bispecific antibody–drug conjugates induced enhanced ICB activity
July 30, 2025
Various approaches have been taken or are underway to improve responses to CTLA-4- or PD-1/PD-L1-directed immune checkpoint blockade (ICB). Making use of nanobodies specific these checkpoints, a nanobody recognizing the murine Ig kappa constant chain (targeting the endogenous antibody...
Meet the newest T cell checkpoint: CD38
July 23, 2025
Immune checkpoint blockade (ICB) can unleash immune responses against a variety of cancers, but its efficacy is often limited by T cell exhaustion. In addition to well established checkpoints like PD-1 and CTLA-4, T cell exhaustion has also been...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
